Study of HuL001 for multiple myeloma that has come back or not responded
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug called HuL001 combined with lenalidomide and dexamethasone for people with multiple myeloma that has returned or stopped responding to at least three prior treatments. It aims to see if this combination can help when other options have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have multiple myeloma that has come back or not responded after at least three prior treatments, or after two treatments that included three different drug types (like an anti-CD38 antibody, a proteasome inhibitor, and an immunomodulatory drug).
- You must have measurable signs of the disease, such as a certain level of M-protein in your blood or urine.
- You must be in fairly good health (able to do daily activities) and have adequate organ function (like blood counts and kidney function).
- You must agree to use effective contraception if you are able to have children.
- You cannot have certain medical conditions like active infections, recent major surgery, or other cancers that haven't been treated and cleared.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SENL103 for people with multiple myeloma that has come back or not responded to several prior treatments. The drug aims to target and kill myeloma cells, potentially helping those who have few other options.
This trial is testing a combination of three drugs (carfilzomib, cyclophosphamide, and dexamethasone) for people with multiple myeloma that has come back or stopped responding to previous treatments, especially if they've already had lenalidomide. The goal is to see if this combination can help control the cancer.
This trial tests a new treatment combination for multiple myeloma that has returned or stopped responding to previous therapy and has spread outside the bone marrow. It aims to see if the combination can shrink these tumors and improve outcomes.
This trial tests a new experimental drug called CM336 for people with multiple myeloma that has come back or stopped responding to standard treatments. The drug may work by helping your immune system attack and destroy myeloma cells. If you join, you will receive the study treatment and be closely monitored to see how well it works and how safe it is.
This study tests a new combination of drugs for people with multiple myeloma that has come back or stopped responding to previous treatments. The goal is to see if the combination helps control the disease.
This trial tests an experimental drug for multiple myeloma that has come back or not responded to at least three previous treatments. It aims to see if the drug can help people whose cancer has progressed despite prior therapies including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
Hear when a new Multiple Myeloma Refractory trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.